Abstract: In some aspects, the present disclosure provides a computer program product for assembling a database comprising electronic data modules, which may be electronic medical records (EMRs). The present disclosure can also be used for purposes such as implementing a system in which physicians and patents can be provided with applications that they can use to confirm that various disease related events have taken place. This can be performed using active diagnosis modules (ADMs) comprising schedules of events. These ADMs and their events can also be used to populate a database which can be used for purposes such as identifying, recruiting and tracking participants in clinical trials.

Abstract: In some aspects, the present disclosure provides a computer program product for assembling a database comprising electronic data modules, which may be electronic medical records (EMRs). The present disclosure can also be used for purposes such as implementing a system in which physicians and patents can be provided with applications that they can use to confirm that various disease related events have taken place. This can be performed using active diagnosis modules (ADMs) comprising schedules of events. These ADMs and their events can also be used to populate a database which can be used for purposes such as identifying, recruiting and tracking participants in clinical trials.

Abstract: The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.

Abstract: The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.